{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:09:35Z","timestamp":1782310175006,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Breast cancer management is shifting towards personalized treatment regimens, particularly for early-stage, hormone receptor positive (HR+) invasive breast cancer (IBC) patients following breast conserving surgery (BCS) where locoregional recurrence (LRR) rates are low. A critical unmet need is the development of tools that can both improve prognostic risk assessment and identify which patients are likely to benefit or not benefit from adjuvant radiation therapy (RT). Herein we developed and cross validated a novel multi-omic assay to assess LRR risk and expected RT benefit for early-stage HR+\/HER2-negative IBCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective multi-institutional cohort of 922 patients (T1-2, N0-1, HR+, HER2-) treated with definitive breast conserving surgery (BCS) with or without adjuvant treatment was used to develop and cross-validate a test to predict IBC LRR after BCS\u2009\u00b1\u2009RT. Treatment assignment was not randomized. The test integrated NGS and proteomic assay data using two biosignatures to generate results: a Decision Score (DS) to predict 10-year LRR prognosis and a radiation resistance index (RRI) to predict differential RT effect on LRR. Associations between DS and RRI with LRR risk and RT interaction were tested using multivariable Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Increasing continuous DS was associated with increasing LRR risk (HR 3.4 per 5 units;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;.001,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009922) after adjusting for clinicopathologic risk factors, while RT was associated with reduced LRR risk (HR 0.2;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; .001). Increasing continuous RRI was associated with increasing LRR risk for patients treated with RT (HR\u2009=\u20093.1 per 5 units; RT: RRI p\n                      <jats:sub>interaction<\/jats:sub>\n                      = 0.002). Biosignature utility was demonstrated for categorical risk groups, which were also associated with differential RT benefit. DS Elevated Risk patients (DS\u2009&gt;\u20095) had higher LRR risk without RT (HR\u2009=\u20094.8;\n                      <jats:italic>p<\/jats:italic>\n                      = .0014) with corresponding 10-year risks of 24% in DS Elevated Risk versus 7% in DS Low Risk (DS\u2009\u2264\u20095). In DS Low Risk patients, a statistically significant reduction in LRR risk (HR\u2009=\u20091.0,\n                      <jats:italic>p<\/jats:italic>\n                      = .96) was not observed. However, in the DS Elevated Risk group, RT was associated with decreased LRR risk (HR\u2009=\u20090.4,\n                      <jats:italic>p<\/jats:italic>\n                      = .0097) for patients with a lower radio resistance index (DS\u2009&gt;\u20095, RRI\u2009\u2264\u20095), whereas RT was not associated with a statistically significant reduction in LRR risk (HR\u2009=\u20090.8,\n                      <jats:italic>p<\/jats:italic>\n                      = .51) for patients with a higher radio resistance index (DS\u2009&gt;\u20095, RRI\u2009&gt;\u20095).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large retrospective, non- randomized multi-institutional cohort, the novel multi-omic biosignature was associated with lower and higher LRR risk after BCS and associated with statistically significant differential RT effect for LRR risk reduction. Clinically meaningful risk groups that were associated with differential RT benefit were identified using the biosignature, supporting its potential utility in the assessment of the LRR risk in early-stage HR+\/HER2-negative IBC. Further clinical validation studies are in process, and prospective validation studies are being planned to establish the role of the test in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02237-4","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:44:16Z","timestamp":1771415056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients"],"prefix":"10.1186","volume":"28","author":[{"given":"Troy","family":"Bremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naamit K.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Krystel-Whittemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton C.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasubramanyam","family":"Karanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G.","family":"Borak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geza","family":"Acs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Al-Hilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Shivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mentrikoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dabbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Savala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat W.","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Wadsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2237_CR1","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019, Collaborative G, Darby S, McGale P et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. Nov 12. 2011;378(9804):1707-16. https:\/\/doi.org\/10.1016\/S0140-6736(11)61629-2","DOI":"10.1016\/S0140-6736(11)61629-2"},{"issue":"22","key":"2237_CR2","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199511303332203","volume":"30","author":"B Fisher","year":"1995","unstructured":"Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med Nov. 1995;30(22):1456\u201361. https:\/\/doi.org\/10.1056\/NEJM199511303332203.","journal-title":"N Engl J Med Nov"},{"issue":"4","key":"2237_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2648.1994.tb01131.x","volume":"19","author":"JE Graydon","year":"1994","unstructured":"Graydon JE. Women with breast cancer: their quality of life following a course of radiation therapy. J Adv Nurs Apr. 1994;19(4):617\u201322. https:\/\/doi.org\/10.1111\/j.1365-2648.1994.tb01131.x.","journal-title":"J Adv Nurs Apr"},{"issue":"10","key":"2237_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa040587","volume":"2","author":"KS Hughes","year":"2004","unstructured":"Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. Sep 2004;2(10):971\u20137. https:\/\/doi.org\/10.1056\/NEJMoa040587.","journal-title":"N Engl J Med"},{"issue":"10","key":"2237_CR5","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2260::AID-CNCR9>3.0.CO;2-M","volume":"15","author":"TJ Whelan","year":"2000","unstructured":"Whelan TJ, Levine M, Julian J, Kirkbride P, Skingley P. The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Ontario clinical oncology group. Cancer May. 2000;15(10):2260\u20136.","journal-title":"Cancer May"},{"issue":"19","key":"2237_CR6","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","volume":"1","author":"KS Hughes","year":"2013","unstructured":"Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus Tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol Jul. 2013;1(19):2382\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.45.2615.","journal-title":"J Clin Oncol Jul"},{"issue":"7","key":"2237_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2207586","volume":"16","author":"IH Kunkler","year":"2023","unstructured":"Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in early breast cancer. N Engl J Med Feb. 2023;16(7):585\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2207586.","journal-title":"N Engl J Med Feb"},{"issue":"35","key":"2237_CR8","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.19.00761","volume":"10","author":"M Sjostrom","year":"2019","unstructured":"Sjostrom M, Chang SL, Fishbane N, et al. Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer. J Clin Oncol Dec. 2019;10(35):3340\u20139. https:\/\/doi.org\/10.1200\/JCO.19.00761.","journal-title":"J Clin Oncol Dec"},{"issue":"8","key":"2237_CR9","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1200\/JCO.22.00655","volume":"10","author":"M Sjostrom","year":"2023","unstructured":"Sjostrom M, Fyles A, Liu FF, et al. Development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer. J Clin Oncol Mar. 2023;10(8):1533\u201340. https:\/\/doi.org\/10.1200\/JCO.22.00655.","journal-title":"J Clin Oncol Mar"},{"issue":"3","key":"2237_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-20-3299","volume":"27","author":"A Stenmark Tullberg","year":"2021","unstructured":"Stenmark Tullberg A, Puttonen HA, Sj\u00f6str\u00f6m M, et al. Immune infiltrate in the primary tumor predicts effect of adjuvant radiotherapy in breast cancer; results from the randomized SweBCG91RT trial. Clin Cancer Res. 2021;27(3):749\u201358.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2237_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/1078-0432.CCR-22-2746","volume":"29","author":"A Stenmark Tullberg","year":"2023","unstructured":"Stenmark Tullberg A, Sj\u00f6str\u00f6m M, Nim\u00e9us E, et al. Integrating tumor-intrinsic and Immunologic factors to identify Immunogenic breast cancers from a low-risk cohort: results from the randomized Swebcg91Rt trial. Clin Cancer Res. 2023;29(9):1783\u201393.","journal-title":"Clin Cancer Res"},{"key":"2237_CR12","doi-asserted-by":"publisher","unstructured":"Stenmark Tullberg A, Sjostrom M, Tran L, et al. Combining histological grade, TILs, and the PD-1\/PD-L1 pathway to identify Immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial. J Immunother Cancer May. 2023;11(5). https:\/\/doi.org\/10.1136\/jitc-2022-006618.","DOI":"10.1136\/jitc-2022-006618"},{"issue":"4","key":"2237_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/jco.23.02270","volume":"42","author":"R Jagsi","year":"2024","unstructured":"Jagsi R, Griffith KA, Harris EE, et al. Omission of radiotherapy after breast-Conserving surgery for women with breast cancer with low clinical and genomic risk: 5-Year outcomes of IDEA. J Clin Oncol. 2024;42(4):390\u20138. https:\/\/doi.org\/10.1200\/jco.23.02270.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2237_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMoa2302344","volume":"17","author":"TJ Whelan","year":"2023","unstructured":"Whelan TJ, Smith S, Parpia S, et al. Omitting radiotherapy after breast-Conserving surgery in luminal A breast cancer. N Engl J Med Aug. 2023;17(7):612\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2302344.","journal-title":"N Engl J Med Aug"},{"key":"2237_CR15","doi-asserted-by":"crossref","unstructured":"Lior Z, Braunstein JW, Deborah A, Dillon Y-H, Chen P, Catalano O, Cahlon MB, El-Tamer R, Jimenez A, Khan C, Perez R, Punglia R, Shiloh L, Warren D, Wazer J, Wright E, Buckley T, King S, Powell E, Winer. Jennifer Bellon. Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cance. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6\u201310; San Antonio, TX Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT1-12-02. 2022.","DOI":"10.1158\/1538-7445.SABCS22-OT1-12-02"},{"issue":"2","key":"2237_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10549-012-2072-y","volume":"134","author":"LJ Solin","year":"2012","unstructured":"Solin LJ, Gray R, Goldstein LJ, et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern cooperative oncology group E2197 study. Breast Cancer Res Treat Jul. 2012;134(2):683\u201392. https:\/\/doi.org\/10.1007\/s10549-012-2072-y.","journal-title":"Breast Cancer Res Treat Jul"},{"issue":"9","key":"2237_CR17","doi-asserted-by":"publisher","first-page":"e2532305","DOI":"10.1001\/jamanetworkopen.2025.32305","volume":"2","author":"DG Miller","year":"2025","unstructured":"Miller DG, Boe LA, Wen HY, et al. Adjuvant radiation and endocrine therapy in early-stage breast cancer with low genomic risk. JAMA Netw Open Sep. 2025;2(9):e2532305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.32305.","journal-title":"JAMA Netw Open Sep"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02237-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:26:10Z","timestamp":1781634370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02237-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2237"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02237-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Bremer, K. Mittal, P. Whitworth, and S. Shivers are employees of PreludeDx and have stock options for the company. T. Bremer and K. Mittal have copyright\/patent\/license\/royalty rights to the Aida test. T. Bremer is the Chief Scientific Officer and P. Whitworth is the Chief Medical Officer of PreludeDx. P. Whitworth is an independent contractor and has ownership equity for Aptitude Health, has grant\/research funding and travel expenses from Agendia, has received research funding from Invitae, Intact Medical, Agendia, and Impedimed, receives compensation from Impedimed, Reverse Medical, Rebound Medical, Lazarus, Cerebrotech, Targeted Medical Education and Medtronic, and is on advisory boards for Medtronic, Lumicell, ImpediMed, and Cianna Medical. C. Shah is a consultant for ImpediMed, Videra Surgical, Evicore, PreludeDx, and has received grant funding from Varian Medical Systems, and VisionRT unrelated to this research. F. Vicini is a consultant for PreludeDx and has executive leadership for MROQC. N. Gerber has received grant\/research funding from PreludeDx, Mount Sinai Icahn School of Medicine, John Theurer Cancer Center, and Accuray. M. Krystel-Whittemore: has received grant\/research funding from PreludeDx. C. Yates: has received uncompensated support from Riptide Bioscience and PreludeDx and has copyright\/patent\/license\/royalty rights from Riptide Bioscience. C. Cox and A. Beard have received research funding from PreludeDx and Agendia. G. Acs is a partner for Ruffolo Hooper & Associates, has courtesy faculty appointment at the University of South Florida Morsani College of Medicine, and is president-elect of the Hungarian Medical Association of America. Z. Al-Hilli, B. Walter, V. Reid and S. Borak declare no conflicts of interests. D. Dabbs, J. Savala, and M. Mentrikoski are independent contractors and have stock options from PreludeDx. C. Wadsten is an independent contractor for Sundsvall Hospital and has received compensation\/payment from Astra Zeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}